摘要
目的探究曼月乐联合米非司酮治疗对围绝经期异常子宫出血并轻中度贫血患者月经量、血红蛋白及性激素的影响。方法选择2019年12月—2021年12月收治的100例围绝经期异常子宫出血并轻中度贫血,依据治疗方案的不同分为联合组54例和曼月乐组46例。比较2组治疗效果,治疗前后经期情况和血红蛋白、性激素水平,以及不良反应发生情况。结果联合组治疗总有效率高于曼月乐组(P<0.05)。2组治疗后经期时间、月经量及子宫内膜厚度均明显缩短或减少(P<0.05);联合组治疗后经期时间、月经量及子宫内膜厚度均短于或少于曼月乐组(P<0.05)。治疗后2组血红蛋白及黄体生成素(LH)、雌二醇(E_(2))、卵泡刺激素(FSH)水平显著改善,且联合组血红蛋白水平显著高于曼月乐组,LH、E_(2)及FSH水平明显低于曼月乐组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论围绝经期异常子宫出血并轻中度贫血患者采用曼月乐联合米非司酮治疗可以减少患者月经量,改善患者血红蛋白及性激素水平,疗效优于单用曼月乐治疗,且安全性较好。
Objective To investigate the effect of Mirena combined with Mifepristone on menstrual volume,hemoglobin and sex hormones in patients with perimenopausal abnormal uterine bleeding(AUB)and mild to moderate anemia.Methods From December 2019 to December 2021,100 patients with perimenopausal abnormal uterine bleeding combined with mild to moderate anemia were selected and divided into the combination group(n=54)and the Mirena group(n=46)according to different treatment schemes.The therapeutic effect,menstrual period,hemoglobin,sex hormone levels and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate of the combination group was higher than that of the Mirena group(P<0.05).After treatment,the menstrual period,menstrual volume and endometrial thickness were significantly shortened or decreased in both groups(P<0.05).The menstruation period,menstrual volume and endometrial thickness in the combination group were shorter or less than those in the Mirena group(P<0.05).After treatment,the levels of hemoglobin,luteinizing hormone(LH),estradiol(E_(2))and follicle stimulating hormone(FSH)in the two groups were significantly improved;the levels of hemoglobin in the combination group were significantly higher than those in the Mirena group,while the levels of LH,E_(2) and FSH were significantly lower than those in the Mirena group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Mirena combined with mifepristone can reduce menstrual volume,improve hemoglobin and sex hormone levels in patients with perimenopausal AUB and mild to moderate anemia.It has better efficacy and safety than Mirena treatment alone.
作者
郭睿
邓春霞
张凡
GUO Rui;DENG Chun-xia;ZHANG Fan(Department of Gynecology and Obstetrics,Beijing Chuiyangliu Hospital,Beijing 100022,China)
出处
《解放军医药杂志》
CAS
2022年第10期85-88,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
北京市自然科学基金资助项目(D191100002817015)。
